WHITE PLAINS, N.Y., April 1, 2011 /PRNewswire/ -- Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.
But for many cancers, such as the blood cancers, early detection is rare, there are no measures that can be taken to prevent the onset of the disease, and they are still killing too many. In these cases, the only solution is continued research to find better treatments and cures once the diagnosis is made.
It is for this reason that many voluntary disease organizations have created programs to accelerate therapies from laboratories to patients. We recognize that funding research is costly and difficult, particularly in these trying economic times, particularly for orphan diseases such as blood cancers where producing these treatments may not always be cost-effective for drug companies.
We have to be more proactive and innovative in our approaches to funding drug development, not only funding laboratory research, but also partnering with biotechnology companies on high-prospect research projects, or by providing much needed expertise to help academics bring their discoveries to market. We are continually searching for new ways to ensure that scientific discoveries are not stuck collecting dust on academic shelves, but are given the boost they need to cross the chasm that swallows so many promising findings.
The Federal government also recognizes this need to get more treatments to patients faster. A key provision of the federal Affordable Care Act that has received little attention is the creation by Congress of the Cures Acceleration Network (CAN). This program, which would be administered by Frances Collins, Ph.D.,
|SOURCE The Leukemia & Lymphoma Society|
Copyright©2010 PR Newswire.
All rights reserved